explore -WSS

explore

author：explore 2025-09-30 23:33:15 - browse：325

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Will an HIV vaccine ever be a reality?

WSS

Medicare innovation center doesn’t save money, experts say

Independent physicians launch a new lobbying group

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Nobel honors Karikó and Weissman's enduring partnership

FDA clears AI tool for detecting skin cancer

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

entertainment

explore

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Study points to new risk in gene therapy death of Terry Horgan

Hepatitis C has a cure — but many Americans still lack access to it

Think you might have Covid

Novavax promises a turnaround & Lilly roils the obesity market

6 solutions to address cancer drug shortages and others

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Health insurers' Q3 question: how much care are people getting?

As demand for Covid shots wanes, Moderna seeks its next success

Copay coupons to count toward deductibles, after Biden court move

Wikipedia

Lawsuit highlights wrinkle for disputes over surprise medical bills

My yearlong odyssey to get my son’s ADHD medication covered

Test for long Covid? Researchers find new clue in blood samples

Independent physicians launch a new lobbying group

FDA clears AI tool for detecting skin cancer

Prior authorization will have to move faster under new Biden rule

explore

focus

hotspot

focus